Cargando…
Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective
Obesity and dyslipidemia are the main features of metabolic syndrome, expressed mainly by adipose tissue dysfunction and connected by similar pathways and pharmacotherapy. Conventional drugs used in these two associated disorders are limited due to poor drug efficiency, non-specificity, and toxic si...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504099/ https://www.ncbi.nlm.nih.gov/pubmed/36145147 http://dx.doi.org/10.3390/nu14183774 |
_version_ | 1784796130770419712 |
---|---|
author | Trandafir, Laura M. Dodi, Gianina Frasinariu, Otilia Luca, Alina C. Butnariu, Lacramioara I. Tarca, Elena Moisa, Stefana M. |
author_facet | Trandafir, Laura M. Dodi, Gianina Frasinariu, Otilia Luca, Alina C. Butnariu, Lacramioara I. Tarca, Elena Moisa, Stefana M. |
author_sort | Trandafir, Laura M. |
collection | PubMed |
description | Obesity and dyslipidemia are the main features of metabolic syndrome, expressed mainly by adipose tissue dysfunction and connected by similar pathways and pharmacotherapy. Conventional drugs used in these two associated disorders are limited due to poor drug efficiency, non-specificity, and toxic side effects. Therefore, novel solutions for tackling obesity-associated diseases and providing insights into the development of innovative or improved therapies are necessary. Targeted nanotherapy is a revolutionary technology, offering a promising solution for combatting the disadvantages of currently available therapies for treating obesity and dyslipidemia due to its superior features, which include specific cell targeting, the protection of drugs against physiological degradation, and sustained drug release. This review presents a brief assessment of obesity and dyslipidemia, their impacts on human health, current treatment, and limitations, and the role and potential use of nanotechnology coupled with targeted drug delivery and nutraceuticals as emerging therapies. To the best of our knowledge, this paper presents, for the first time in the literature, a comparison between obesity and dyslipidemia nano-formulations based on drugs and/or natural extracts applied in experimental studies. |
format | Online Article Text |
id | pubmed-9504099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95040992022-09-24 Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective Trandafir, Laura M. Dodi, Gianina Frasinariu, Otilia Luca, Alina C. Butnariu, Lacramioara I. Tarca, Elena Moisa, Stefana M. Nutrients Review Obesity and dyslipidemia are the main features of metabolic syndrome, expressed mainly by adipose tissue dysfunction and connected by similar pathways and pharmacotherapy. Conventional drugs used in these two associated disorders are limited due to poor drug efficiency, non-specificity, and toxic side effects. Therefore, novel solutions for tackling obesity-associated diseases and providing insights into the development of innovative or improved therapies are necessary. Targeted nanotherapy is a revolutionary technology, offering a promising solution for combatting the disadvantages of currently available therapies for treating obesity and dyslipidemia due to its superior features, which include specific cell targeting, the protection of drugs against physiological degradation, and sustained drug release. This review presents a brief assessment of obesity and dyslipidemia, their impacts on human health, current treatment, and limitations, and the role and potential use of nanotechnology coupled with targeted drug delivery and nutraceuticals as emerging therapies. To the best of our knowledge, this paper presents, for the first time in the literature, a comparison between obesity and dyslipidemia nano-formulations based on drugs and/or natural extracts applied in experimental studies. MDPI 2022-09-13 /pmc/articles/PMC9504099/ /pubmed/36145147 http://dx.doi.org/10.3390/nu14183774 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Trandafir, Laura M. Dodi, Gianina Frasinariu, Otilia Luca, Alina C. Butnariu, Lacramioara I. Tarca, Elena Moisa, Stefana M. Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective |
title | Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective |
title_full | Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective |
title_fullStr | Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective |
title_full_unstemmed | Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective |
title_short | Tackling Dyslipidemia in Obesity from a Nanotechnology Perspective |
title_sort | tackling dyslipidemia in obesity from a nanotechnology perspective |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504099/ https://www.ncbi.nlm.nih.gov/pubmed/36145147 http://dx.doi.org/10.3390/nu14183774 |
work_keys_str_mv | AT trandafirlauram tacklingdyslipidemiainobesityfromananotechnologyperspective AT dodigianina tacklingdyslipidemiainobesityfromananotechnologyperspective AT frasinariuotilia tacklingdyslipidemiainobesityfromananotechnologyperspective AT lucaalinac tacklingdyslipidemiainobesityfromananotechnologyperspective AT butnariulacramioarai tacklingdyslipidemiainobesityfromananotechnologyperspective AT tarcaelena tacklingdyslipidemiainobesityfromananotechnologyperspective AT moisastefanam tacklingdyslipidemiainobesityfromananotechnologyperspective |